Evidence map›Paper›PMID 36744151›Full record

ArticleFrontiers in medicine2023

Clinical experience: Outcomes of mesenchymal stem cell transplantation in five stroke patients.

Nesrin Ercelen, Nilgun Karasu, Bulent Kahyaoglu, Onder Cerezci, Rana Cagla Akduman, Defne Ercelen, Gizem Erturk, Gokay Gulay, Nagihan Alpaydin, Gizem Boyraz and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Nesrin ErcelenDepartment of Medical Genetics, Faculty of Medicine, Üsküdar University, Istanbul, Türkiye.
Nilgun KarasuDepartment of Medical Genetics, Faculty of Medicine, Üsküdar University, Istanbul, Türkiye.
Bulent KahyaogluDepartment of Neurology, American Hospital, Istanbul, Türkiye.
Onder CerezciDepartment of Physical Therapy and Rehabilitation, Faculty of Medicine, Üsküdar University, Istanbul, Türkiye.
Rana Cagla AkdumanDepartment of Neurology, Faculty of Medicine, Yeditepe University, Istanbul, Türkiye.
Defne ErcelenComputational and Systems Biology Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA, United States.
Gizem ErturkDepartment of Neurology, American Hospital, Istanbul, Türkiye.
Gokay GulayATIGEN-CELL/Cell and Tissue Center, Trabzon, Türkiye.
Nagihan AlpaydinATIGEN-CELL/Cell and Tissue Center, Trabzon, Türkiye.
Gizem BoyrazGeneis Genetic System Solutions, Istanbul, Türkiye.
Berrin MonteleoneDepartment of Pediatrics at NYU Long Island School of Medicine, Medical Genetics, Langone Hospital, New York University, Long Island, NY, United States.
Zekiye KuralDepartment of Neurology, American Hospital, Istanbul, Türkiye.
Hakan SilekDepartment of Neurology, Faculty of Medicine, Yeditepe University, Istanbul, Türkiye.
Sibel TemurDepartment of Anesthesia and Reanimation, Faculty of Medicine, Yeditepe University, Istanbul, Türkiye.
Canan Aykut BingolDepartment of Neurology, Faculty of Medicine, Yeditepe University, Istanbul, Türkiye.
Yeditepe University · TRAmerikan Hastanesi · TRÜsküdar University · TRNYU Langone Health · USUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stem cell therapy, which has promising results in acute disorders such as stroke, supports treatment by providing rehabilitation in the chronic stage patients. In acute stroke, thrombolytic medical treatment protocols are clearly defined in neurologic emergencies, but in neurologic patients who miss the "thrombolytic treatment intervention window," or in cases of hypoxic-ischemic encephalopathy, our hands are tied, and we are still unfortunately faced with hopeless clinical implementations. We consider mesenchymal stem cell therapy a viable option in these cases. In recent years, novel research has focused on neuro-stimulants and supportive and combined therapies for stroke. Currently, available treatment options are limited, and only certain patients are eligible for acute treatment. In the scope of our experience, five stroke patients were evaluated in this study, who was treated with a single dose of 1-2 × 10

Indexed as

regenerative medicinerehabilitationstem cell therapystroke recoveryUC-MSC transplantation

Identifiers

PMID36744151
PMCPMC9892908
OpenAlexW4317401753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.